Ken Kato summarizes combination regimens currently investigated in the neoadjuvant treatment of patients with esophageal cancer and outlines how immunotherapy has changed the first-line treatment standards in patients with esophageal squamous-cell carcinoma and which further developments are expected for the first-and second-line setting in the future.

Here is the full ESMO 2021 Solid Tumors report.